DGAP-Adhoc: Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE
DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Alliance
Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE
10-Sep-2020 / 14:48 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Disclosure of Insider Information pursuant to Section 17 (1) 1 of the Regulation (EU)
No. 596/2014 on Market Abuse, as amended
(Market Abuse Regulation - MAR)
Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE
Grünwald, September 10, 2020 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) and BioNTech SE, Mainz, Germany, have agreed that their production subsidiaries will cooperate on producing a COVID-19 vaccine. The production capacities at Dermapharm will be available to the cooperation partners BioNTech SE and Pfizer Inc. already when production of the vaccine begins.
>End of the ad hoc announcement<
Contacts
Investor Relations &
Corporate Communications
Britta Hamberger
Phone: +49 (0)89 - 64186-233
Fax: +49 (0)89 - 64186-165
e-mail: ir@dermapharm.com
cometis AG
Claudius Krause
Phone: +49 (0)611 - 205855-28
Fax: +49 (0)611 - 205855-66
e-mail: ir@dermapharm.com
10-Sep-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
End of Announcement DGAP News Service
1129961 10-Sep-2020 CET/CEST